The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
EC Approves Ustekinumab Biosimilar
Celltrion announced that the EC has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of various chronic inflammatory diseases.1 SteQeyma is approved for use in gastroenterology, dermatology, and rheumatology, expanding treatment options for conditions such as Crohn disease. Stelara, the reference product, was the first biologic to target interleukin (IL)-12 and IL-23, cytokines essential to immune and inflammatory responses.
The decision was based on comprehensive clinical evidence, including a phase 3 study in patients with moderate to severe plaque psoriasis, which demonstrated that SteQeyma is highly similar to Stelara in terms of efficacy and safety, with no clinically meaningful differences.
Commenting on the approval, Taehun Ha, senior vice president and head of Europe division at Celltrion, said, “The EC approval of SteQeyma brings an important new therapeutic option to patients, and we’re excited to launch this innovative therapy, with a proven track record in Crohn’s and other immune diseases….This approval, alongside those of Remsima SC [Zymfentra in the US] and Yuflyma [adalimumab biosimilar], marks a key milestone in our strategy to strengthen Celltrion’s immunology offering, and with the recent approval of Omlyclo in May, we are looking forward to expanding our portfolio into the dermatology sector.”
SteQeyma is now Celltrion’s seventh biosimilar approved in the European Union, joining its portfolio that includes Remsima SC, Yuflyma, and other prominent biosimilars like Truxima (rituximab biosimilar) and Herzuma (trastuzumab biosimilar).
Zymfentra and Adalimumab Biosimilar Expansion
Celltrion USA announced an agreement with Cigna Healthcare and Express Scripts to expand patient access to Zymfentra (infliximab-dyyb), the only FDA-approved subcutaneous infliximab.2 Effective August 1, 2024, Zymfentra will be listed as a preferred medication on Cigna’s medical formulary, covering 16.1 million insured lives.
Approved by the FDA in 2023, Zymfentra is used for maintenance therapy in adults with ulcerative colitis and Crohn’s disease after intravenous infliximab treatment. Although Zymfentra is deemed a biosimilar or a biobetter in international markets, it was approved as a novel agent in the US. The agreement aims to offer patients more flexibility and treatment options. This follows Express Scripts’ earlier move to list Zymfentra on its National Preferred Formulary.
Additionally, MedImpact Healthcare Systems, the largest independent provider of health solutions in the US, is expanding access to biosimilars referencing Humira (adalimumab), including the branded and unbranded versions of Simlandi (adalimumab-adaz), for patients with conditions like Crohn disease and rheumatoid arthritis.3 New patients can access these biosimilars through their pharmacy benefit, while those already taking Humira can continue doing so.
Patients switching from biosimilars can also return to Humira if needed. MedImpact said it prioritizes clinical interchangeability and affordability, offering biosimilars at the same cost as Humira, with flexibility in pharmacy options. This move aligns with MedImpact’s commitment to patient-centered, cost-effective care, ensuring supply chain stability and adding new biosimilars as they meet clinical and economic criteria.
Biosimilar Policy Briefing
The Association for Accessible Medicines (AAM) and its Biosimilars Council recently held a policy briefing for Congressional staff, addressing barriers preventing patient access to low-cost generic and biosimilar medicines, as reported by Drug Store News.4
The discussion focused on patent-related issues, such as patent thickets, settlements, and “skinny labeling,” and their impact on drug prices. David Gaugh, AAM’s interim president and CEO, emphasized that while generics and biosimilars significantly lower drug costs, patent thickets often hinder these savings.
The panel featured legal and industry experts, including representatives from AAM, Goodwin Procter, Sandoz, and Apotex. AAM, along with other organizations, also sent a letter to Congress advocating for legislation to stop patent thickets and reform pharmacy benefit manager practices that obstruct generic and biosimilar adoption.
Additionally, AAM released its 2024 U.S. Generic & Biosimilar Medicines Savings Report, showing that in 2023, the use of generics and biosimilars saved the US health care system $445 billion.
References
1. European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases. Celltrion. Press release; August 25, 2024. Accessed September 17, 2024. https://www.businesswire.com/news/molecularlab/20240819920486/en/European-Commission-approves-Celltrion%E2%80%99s-SteQeyma%C2%AE-CT-P43-a-biosimilar-to-Stelara%C2%AE-ustekinumab-for-the-treatment-of-multiple-chronic-inflammatory-diseases
2. Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA™ (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary. Celltrion USA. Press release; August 28, 2024. Accessed September 17, 2024. https://www.celltrion.com/en-us/company/media-center/press-release/3212
3. MedImpact expands access to two Humira biosimilars for new patients. MedImpact Healthcare Systems. Press release; August 27, 2024. Accessed September 17, 2024. https://www.medimpact.com/clients/resources/press-releases/medimpact-expands-access-two-humira-biosimilars-new-patients
4. Levy S. AAM, Biosimilar Council host patent abuse Congressional briefing. Drug Store News. September 16, 2024. Accessed September 17, 2024. https://drugstorenews.com/aam-biosimilar-council-host-patent-abuse-congressional-briefing
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.